Ipsen Biopharmaceuticals; marketed in US aesthetics by Galderma
Dysport
A prescription botulinum toxin type A injection used to temporarily improve labelled glabellar lines by reducing targeted muscle activity.
Botulinum toxin type A neuromodulatorReviewed 7/30/2026Source recorded
At a glance
| Primary purpose | Temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adults younger than 65 under the US cosmetic label. |
|---|---|
| Mechanism | Acts at the neuromuscular junction to inhibit acetylcholine release and temporarily reduce activity in injected muscles. |
| When results appear | Clinical cosmetic outcomes are assessed after treatment; visible change commonly develops over the first days to two weeks, but individual onset varies. |
| Typical sessions | One treatment visit; the US label states treatment should not occur more frequently than every three months. |
| Downtime | No formal recovery period is specified, but injection-site reactions and unwanted weakness can occur. |
| Longevity | Temporary; the US label limits retreatment frequency to no more often than every three months rather than promising an exact duration for every patient. |
| Reversibility | Not immediately reversible; effects generally diminish as neuromuscular function recovers. |
| Documented risks | Eyelid ptosis, headache, injection-site reactions, hypersensitivity including to cow's-milk protein, infection-site contraindication, and rare distant spread of toxin effect with swallowing or breathing difficulty. |
| Most common disappointment | The US cosmetic indication is narrower than Botox Cosmetic's current label, and static lines or volume loss may persist. |
| Common marketing misconception | A Dysport unit is not equivalent to a Botox unit and no direct unit conversion should be presented. |
| What varies by provider | Label-appropriate patient selection, dose, injection pattern, anatomy, symmetry, and spread into adjacent muscles. |
| When this treatment may not be appropriate | Contraindicated with hypersensitivity to any botulinum toxin product or cow's-milk protein and with infection at the proposed site; prescriber review is required for other warnings. |
| United States regulatory status | FDA-approved prescription biologic for temporary improvement of moderate to severe glabellar lines associated with procerus and corrugator activity in adult patients younger than 65. |
| Canadian regulatory status | Health Canada Drug Product Database lists Dysport Aesthetic DIN 02387735 as marketed; use must follow the current Canadian product monograph. |
| Evidence status | High for product identity, labelled indication, dose-frequency limit, contraindications, and non-interchangeability; comparative onset or superiority claims are not established here. |
Sources
- DYSPORT prescribing informationregulator
- DYSPORT US Prescribing InformationFDA prescribing information · regulatory-primary · supports 25 profile fields
- Health Canada Drug Product Database: Dysport Aesthetic DIN 02387735Health Canada DPD · regulatory-primary
Related comparisons
See average treatment prices near you
Enter a US ZIP code or Canadian postal code to check our stored estimate for the surrounding market.